Notices by Anti. 🐘 (antiaall3s@chaos.social)

At the start of December i got a Pfizer COVID booster. It has fucked me up. Ever since then i have not had one day of getting back to baseline. Chest pain, tachycardia, brain fog, vertigo, tinnitus, nausea, belly ache, swollen lymph nodes.

It has set me back months, if not years.

The worst of it is that i had zero reactions to Novovax last year. And i have had bad reactions to Pfizer before.

But Switzerland has failed to secure Novovax ever since 2023.

Vaccinations are great, they saved a lot of lives.

But people who had bad reactions before should not have to vaccinate.

But when almost no one else continues to vaccinate, i felt like i needed to take the risk.

And my body is paying the price.

Let the record show: Almost three months on and i am still struggling. I am still miles away from the baseline that i had reached before the covid vaccination that has fucked me up.

It is an absurd situation, that i as someone who has always had strong adverse reactions to mrna vaccines, felt pressured into getting it, because almost everyone else stopped getting them.

"Chronic pain is a teacher, though a cruel one. It forces slowness. It demands attention. It collapses the capitalist timeline that says every minute must be monetized. In this way, the disabled and the chronically ill embody a radical politics of time.
[...]
The left often talks about revolution in terms of power, but rarely in terms of tenderness.

Yet no revolution will last if it does not make room for the fragile, the slow, the wounded."

https://anarchistjew.substack.com/p/i-grow-desperate-for-community

✅

· Researchers state that post-vaccine syndrome is characterized by persistent immune dysregulation & issues with blood coagulation.

· A drug called dapagliflozin, used to treat Type 2 Diabetes, is being investigated for #LongCOVID in a clinical trial.

· A double-blind clinical trial is evaluating an experimental drug called REGN7544 for people with postural orthostatic tachycardia syndrome (POTS).

https://thesicktimes.org/2025/05/06/research-updates-may-6/

#ResearchUpdate

· The Bateman Horne Center and Open Medicine Foundation recently released a highly anticipated ME and Long COVID clinical care guide.
· Researchers estimate a higher rate of new-onset diabetes after SARS-C0V-2 infection in a systematic review in Emerging Microbes and Infections
· A new preprint in Medxriv further demonstrates that Long COVID and ME are not deconditioning.

https://thesicktimes.org/2025/05/13/research-updates-may-13/

#ResearchUpdate #TheSickTimes

· #LongCOVID clinical trial assessing the monoclonal antibody AER002 found no difference between those who got the drug and placebo

· prospective study in Pediatric International found that, six months after SARS-C0V-2 infection, 23% of children had Long COVID symptoms

· Chinese study of five participants with Long COVID and myocarditis found severe damage in the mitochondria

https://thesicktimes.org/2025/05/20/research-updates-may-20/

#ResearchUpdate #COVID19

· A large study in Nature Genetics found a genetic risk factor for developing #LongCOVID
· Leading Long COVID and myalgic encephalomyelitis (ME) researchers have pushed back against an op-ed commissioned by the BMJ that spread false claims about #MECFS
· RECOVER-Treating Long COVID (TLC), the clinical trials initiative from the National Institutes of Health’s flagship Long COVID research program, shared updates about forthcoming trials

https://thesicktimes.org/2025/05/27/research-updates-may-27/

#ResearchUpdate #COVID19

· New NIH study found that around one in seven children under age six with a prior SARS-CoV-2 infection met the probable diagnostic criteria for #LongCOVID
· Pemivibart (Pemgarda), a monoclonal antibody that helps prevent COVID-19, was found to be “well tolerated” and effective in phase 3 clinical trial
· New preprint from researchers in the US & Canada used a model called “Mobius” to classify ME & Long COVID with 97% accuracy, using data from blood

https://thesicktimes.org/2025/06/03/research-updates-june-3/

#ResearchUpdate

· Three recent studies show the harmful effects of misdiagnosis for chronic diseases and conditions
· A new preprint shared in Research Square found a connection between post-exertional malaise (PEM) and microclots, or tiny blood clots that disrupt how oxygen moves through the body
· The Cohen Center for Recovery from Complex Chronic Illness (CoRE) at Mount Sinai in New York is now recruiting for their rapamycin clinical trial for #LongCOVID

https://thesicktimes.org/2025/06/10/research-updates-june-10/

#COVID19 #ResearchUpdate

· Pregnant people infected with SARS-CoV-2 during first trimester more likely to have smaller newborns
· Children with multisystem inflammatory syndrome (MIS-C) triggered by COVID-19 had metabolic disturbances that “mirrored those seen in severe adult #COVID19 patients
· A population-level study from a database in Utah found there was a significant association between a past COVID-19 diagnosis and self-harming in children and adolescents

https://thesicktimes.org/2025/06/17/research-updates-june-17/

#ResearchUpdate

· A new review paper published in Psychiatry and Clinical Neurosciences focuses on how Long COVID impacts the nervous and immune systems
· Another study has found potential biomarkers in the blood of people with myalgic encephalomyelitis (ME)
· The Patient-Led Research Collaborative (PLRC) launched a new clinical trial and research study platform for Long COVID and associated diseases: the PLRC Registry

https://thesicktimes.org/2025/06/24/research-updates-june-24/

#ResearchUpdate #LongCOVID #MECFS

· Scientists found a new antiviral drug prototype that prevented Long COVID in mice and could also help treat the disease
· A recent preprint shared in medRxiv found further evidence of brain damage after COVID-19
· A new clinical trial for myalgic encephalomyelitis (ME) is recruiting in Tokyo, Japan, to test the monoclonal antibody Rituximab

https://thesicktimes.org/2025/07/01/research-updates-july-1/

#ResearchUpdate #COVID19

· The biotech company Invivyd, which makes the #COVID19 monoclonal antibody Pemgarda, announced that it has launched the SPEAR Study Group to explore the drug for #LongCOVID and post-vaccine syndrome (PVS)
· A new study from Taiwan published in Pediatrics and Neonatology found about 14% of children developed Long COVID after being infected with #SarsCoV2
· A new observational study is investigating the relationship between COVID-19 and #Diabetes

https://thesicktimes.org/2025/07/08/research-updates-july-8/

#ResearchUpdate

· A new study in PNAS found elevated oxidative stress was a shared characteristic in both #MECFS and #LongCOVID
· RECOVER-Treating Long COVID, the clinical trials initiative run by the Foundation for the NIAID, has announced that it will hold a second annual hybrid workshop discussing the initiative’s research
· A clinical trial in the U.K. called PHOSP-I is recruiting to test the monoclonal antibody Tocilizumab

https://thesicktimes.org/2025/07/15/research-updates-july-15/

#ResearchUpdate #COVID19

· A treatment for cats with a #COVID19-related infection may help advance #LongCOVID research
· The supplement Oxaloacetate may help reduce fatigue for LC, but it “did not reach statistical significance,” according to a new study at Bateman Horne Center
· A new prospective cohort study in JAMA Oncology of 1,572 participants with cancer found that COVID-19 had a “significant impact” on these patients, incl. hospitalization, treatment disruptions, death

https://thesicktimes.org/2025/07/22/research-updates-july-22/

#ResearchUpdate

· Two studies on potential biomarkers for #MECFS were published this month
· Stellate ganglion blocks, a procedure where an anesthetic is injected into nerves in the neck, may help reduce the severity of some symptoms of #LongCOVID and ME
· An observational study is recruiting 40 people in Boston, Massachusetts to test for defects of air and blood flow in the lungs in people with Long COVID

https://thesicktimes.org/2025/07/29/research-updates-july-29/

#ResearchUpdate #COVID19

· A drug originally developed for celiac disease was found to be safe and effective in treating a post-COVID syndrome in children
· “Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames,” said one of the authors of a new study in Nature
· An upcoming at-home clinical trial program for #LongCOVID, run by Scripps Research, is seeking participants

https://thesicktimes.org/2025/08/05/research-updates-august-5/

#ResearchUpdates #COVID19

· People with myalgic encephalomyelitis (#MECFS) have significant genetic differences in their DNA
· A very small clinical trial of the infusion drug BC 007 published in eClinicalMedicine found “significant improvement” in fatigue in people with #LongCOVID
· A phase 2 clinical trial testing the monoclonal antibody sipavibart is recruiting in Fort Lauderdale, Florida

https://thesicktimes.org/2025/08/12/research-updates-august-12/

#ResearchUpdates #COVID19